Teva Pharmaceutical Indus Analyst Ratings
Teva Pharmaceutical Indus Analyst Ratings
梯瓦製藥工業分析師評級
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/08/2023 | 36.34% | B of A Securities | $12 → $13 | Maintains | Buy |
| 07/06/2023 | -16.1% | UBS | $7 → $8 | Upgrades | Sell → Neutral |
| 05/25/2023 | 4.88% | Morgan Stanley | → $10 | Initiates Coverage On | → Equal-Weight |
| 05/18/2023 | — | Evercore ISI Group | Upgrades | In-Line → Outperform | |
| 05/11/2023 | 15.36% | B of A Securities | $13 → $11 | Maintains | Buy |
| 02/09/2023 | 46.83% | Barclays | $13 → $14 | Maintains | Overweight |
| 01/19/2023 | 25.85% | Jefferies | $10 → $12 | Downgrades | Buy → Hold |
| 11/23/2022 | -26.59% | Piper Sandler | $8 → $7 | Maintains | Underweight |
| 11/14/2022 | 4.88% | JP Morgan | $11 → $10 | Downgrades | Neutral → Underweight |
| 11/07/2022 | 4.88% | BMO Capital | $11 → $10 | Maintains | Market Perform |
| 10/21/2022 | 4.88% | Jefferies | → $10 | Assumes | → Buy |
| 08/05/2022 | 36.34% | B of A Securities | $10 → $13 | Upgrades | Neutral → Buy |
| 08/02/2022 | 4.88% | Goldman Sachs | $9 → $10 | Maintains | Neutral |
| 06/14/2022 | 4.88% | UBS | → $10 | Initiates Coverage On | → Neutral |
| 05/17/2022 | -5.61% | B of A Securities | → $9 | Upgrades | Underperform → Neutral |
| 05/12/2022 | -5.61% | Goldman Sachs | $10 → $9 | Maintains | Neutral |
| 05/04/2022 | -26.59% | Piper Sandler | $11 → $7 | Downgrades | Neutral → Underweight |
| 04/05/2022 | 36.34% | Barclays | $11 → $13 | Upgrades | Equal-Weight → Overweight |
| 02/18/2022 | 15.36% | Barclays | $13 → $11 | Maintains | Equal-Weight |
| 01/27/2022 | — | Argus Research | Downgrades | Buy → Hold | |
| 10/28/2021 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 07/29/2021 | 46.83% | Raymond James | $15 → $14 | Maintains | Outperform |
| 07/29/2021 | 15.36% | Wells Fargo | $12 → $11 | Maintains | Equal-Weight |
| 05/04/2021 | 15.36% | UBS | $15 → $11 | Downgrades | Buy → Neutral |
| 11/25/2020 | — | Oppenheimer | Initiates Coverage On | → Perform | |
| 11/06/2020 | 15.36% | BMO Capital | $13 → $11 | Maintains | Market Perform |
| 08/06/2020 | 36.34% | Barclays | → $13 | Upgrades | Underweight → Equal-Weight |
| 08/06/2020 | 46.83% | SVB Leerink | $13 → $14 | Maintains | Market Perform |
| 07/27/2020 | 25.85% | Goldman Sachs | → $12 | Initiates Coverage On | → Neutral |
| 06/01/2020 | 67.8% | SunTrust Robinson Humphrey | $11 → $16 | Upgrades | Hold → Buy |
| 05/11/2020 | 57.32% | UBS | $12 → $15 | Maintains | Buy |
| 05/08/2020 | 25.85% | SVB Leerink | $11 → $12 | Maintains | Market Perform |
| 05/08/2020 | -16.1% | B of A Securities | $7 → $8 | Reiterates | → Underperform |
| 04/15/2020 | -16.1% | Piper Sandler | $10 → $8 | Maintains | Neutral |
| 04/06/2020 | — | UBS | Upgrades | Neutral → Buy | |
| 04/02/2020 | -16.1% | Morgan Stanley | $13 → $8 | Maintains | Underweight |
| 03/23/2020 | -26.59% | B of A Securities | $11 → $7 | Maintains | Underperform |
| 03/05/2020 | 25.85% | Wells Fargo | $10 → $12 | Maintains | Equal-Weight |
| 02/18/2020 | 57.32% | Argus Research | $10 → $15 | Maintains | Buy |
| 02/14/2020 | 36.34% | Morgan Stanley | $8 → $13 | Maintains | Underweight |
| 02/13/2020 | 15.36% | B of A Securities | $8 → $11 | Maintains | Underperform |
| 02/13/2020 | 36.34% | SunTrust Robinson Humphrey | $9 → $13 | Maintains | Hold |
| 02/13/2020 | 67.8% | Oppenheimer | $12 → $16 | Maintains | Outperform |
| 02/12/2020 | 57.32% | Cantor Fitzgerald | $9 → $15 | Maintains | Neutral |
| 02/12/2020 | 36.34% | CFRA | $11 → $13 | Maintains | Hold |
| 01/22/2020 | 4.88% | Wells Fargo | $8 → $10 | Maintains | Equal-Weight |
| 11/12/2019 | — | JP Morgan | Upgrades | Underweight → Neutral | |
| 11/08/2019 | -26.59% | Piper Sandler | $6 → $7 | Maintains | Neutral |
| 10/17/2019 | — | Gabelli & Co. | Upgrades | Hold → Buy | |
| 09/30/2019 | -16.1% | Wells Fargo | $17 → $8 | Maintains | Market Perform |
| 09/12/2019 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 09/06/2019 | -26.59% | JP Morgan | $9 → $7 | Maintains | Underweight |
| 08/09/2019 | -5.61% | BMO Capital | $11 → $9 | Maintains | Market Perform |
| 07/15/2019 | -37.07% | Morgan Stanley | $16 → $6 | Downgrades | Equal-Weight → Underweight |
| 07/10/2019 | — | Credit Suisse | Assumes | → Neutral | |
| 06/11/2019 | -16.1% | Barclays | → $8 | Initiates Coverage On | → Underweight |
| 06/03/2019 | 25.85% | Oppenheimer | → $12 | Upgrades | Perform → Outperform |
| 05/30/2019 | -5.61% | B of A Securities | $19 → $9 | Downgrades | Buy → Underperform |
| 05/28/2019 | 25.85% | UBS | $22 → $12 | Downgrades | Buy → Neutral |
| 05/09/2019 | 78.29% | Wells Fargo | $18 → $17 | Maintains | Market Perform |
| 04/11/2019 | 141.22% | Citigroup | $27 → $23 | Maintains | Buy |
| 04/03/2019 | 88.78% | Wells Fargo | $20 → $18 | Maintains | Market Perform |
| 03/28/2019 | 88.78% | BMO Capital | → $18 | Initiates Coverage On | → Market Perform |
| 03/20/2019 | 78.29% | SunTrust Robinson Humphrey | → $17 | Initiates Coverage On | → Hold |
| 03/07/2019 | 130.73% | UBS | → $22 | Reinstates | → Buy |
| 03/06/2019 | 78.29% | Morgan Stanley | → $17 | Downgrades | Overweight → Equal-Weight |
| 02/14/2019 | 109.75% | Credit Suisse | $26 → $20 | Maintains | Neutral |
| 02/14/2019 | — | Raymond James | Upgrades | Market Perform → Outperform | |
| 01/23/2019 | 67.8% | Piper Sandler | $15 → $16 | Upgrades | Underweight → Neutral |
| 01/03/2019 | — | B of A Securities | Upgrades | Underperform → Buy | |
| 11/05/2018 | 183.17% | Morgan Stanley | → $27 | Upgrades | Equal-Weight → Overweight |
| 11/02/2018 | 109.75% | B of A Securities | $19 → $20 | Maintains | Underperform |
| 10/01/2018 | 214.63% | Goldman Sachs | → $30 | Maintains | Buy |
| 10/01/2018 | — | Leerink Swann | Upgrades | Underperform → Market Perform | |
| 09/17/2018 | 204.14% | Mizuho | $28 → $29 | Maintains | Buy |
| 09/17/2018 | 172.68% | Credit Suisse | $23 → $26 | Maintains | Neutral |
| 09/17/2018 | — | BTIG | Upgrades | Sell → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/08/2023 | 36.34% | B of A證券 | $12→$13 | 維護 | 買 |
| 07/06/2023 | -16.1% | 瑞銀集團 | $7→$8 | 升級 | 賣出→中性 |
| 2023年05月25日 | 4.88% | 摩根士丹利 | →$10 | 開始承保 | →等重 |
| 2023年05月18日 | - | Evercore ISI集團 | 升級 | 線內→表現優異 | |
| 2023年05月11日 | 15.36% | B of A證券 | $13→$11 | 維護 | 買 |
| 02/09/2023 | 46.83% | 巴克萊 | $13→$14 | 維護 | 超重 |
| 2023年1月19日 | 25.85% | 傑富瑞 | $10→$12 | 評級下調 | 購買→Hold |
| 2022年11月23日 | -26.59% | 派珀·桑德勒 | $8→$7 | 維護 | 體重不足 |
| 2022年11月14日 | 4.88% | 摩根大通 | $11→$10 | 評級下調 | 中性→減持 |
| 11/07/2022 | 4.88% | 蒙特利爾銀行資本 | $11→$10 | 維護 | 市場表現 |
| 2022年10月21日 | 4.88% | 傑富瑞 | →$10 | 假設 | →購買 |
| 08/05/2022 | 36.34% | B of A證券 | $10→$13 | 升級 | 中性→購買 |
| 08/02/2022 | 4.88% | 高盛 | $9→$10 | 維護 | 中性 |
| 2022/06/14 | 4.88% | 瑞銀集團 | →$10 | 開始承保 | →中性 |
| 2022/05/17 | -5.61% | B of A證券 | →$9 | 升級 | 表現不佳的→中性 |
| 2022年05月12日 | -5.61% | 高盛 | $10→$9 | 維護 | 中性 |
| 05/04/2022 | -26.59% | 派珀·桑德勒 | $11→$7 | 評級下調 | 中性→減持 |
| 04/05/2022 | 36.34% | 巴克萊 | $11→$13 | 升級 | 等重→超重 |
| 02/18/2022 | 15.36% | 巴克萊 | $13→$11 | 維護 | 等重 |
| 2022年01月27日 | - | Argus研究 | 評級下調 | 購買→Hold | |
| 10/28/2021 | - | 雷蒙德·詹姆斯 | 評級下調 | 跑贏→市場表現 | |
| 07/29/2021 | 46.83% | 雷蒙德·詹姆斯 | $15→$14 | 維護 | 跑贏大盤 |
| 07/29/2021 | 15.36% | 富國銀行 | $12→$11 | 維護 | 等重 |
| 05/04/2021 | 15.36% | 瑞銀集團 | $15→$11 | 評級下調 | 購買→中性 |
| 11/25/2020 | - | 奧本海默 | 開始承保 | →性能 | |
| 11/06/2020 | 15.36% | 蒙特利爾銀行資本 | $13→$11 | 維護 | 市場表現 |
| 08/06/2020 | 36.34% | 巴克萊 | →$13 | 升級 | 重量不足的→等重 |
| 08/06/2020 | 46.83% | SVB Leerink | $13→$14 | 維護 | 市場表現 |
| 07/27/2020 | 25.85% | 高盛 | →$12 | 開始承保 | →中性 |
| 06/01/2020 | 67.8% | SunTrust Robinson Humphrey | $11→$16 | 升級 | 持有→購買 |
| 05/11/2020 | 57.32% | 瑞銀集團 | $12→$15 | 維護 | 買 |
| 05/08/2020 | 25.85% | SVB Leerink | $11→$12 | 維護 | 市場表現 |
| 05/08/2020 | -16.1% | B of A證券 | $7→$8 | 重申 | →表現不佳 |
| 04/15/2020 | -16.1% | 派珀·桑德勒 | $10→$8 | 維護 | 中性 |
| 04/06/2020 | - | 瑞銀集團 | 升級 | 中性→購買 | |
| 04/02/2020 | -16.1% | 摩根士丹利 | $13→$8 | 維護 | 體重不足 |
| 03/23/2020 | -26.59% | B of A證券 | $11→$7 | 維護 | 表現不佳 |
| 03/05/2020 | 25.85% | 富國銀行 | $10→$12 | 維護 | 等重 |
| 02/18/2020 | 57.32% | Argus研究 | $10→$15 | 維護 | 買 |
| 02/14/2020 | 36.34% | 摩根士丹利 | $8→$13 | 維護 | 體重不足 |
| 02/13/2020 | 15.36% | B of A證券 | $8→$11 | 維護 | 表現不佳 |
| 02/13/2020 | 36.34% | SunTrust Robinson Humphrey | $9→$13 | 維護 | 保持 |
| 02/13/2020 | 67.8% | 奧本海默 | $12→$16 | 維護 | 跑贏大盤 |
| 02/12/2020 | 57.32% | 康託·菲茨傑拉德 | $9→$15 | 維護 | 中性 |
| 02/12/2020 | 36.34% | CFRA | $11→$13 | 維護 | 保持 |
| 2020/01/22 | 4.88% | 富國銀行 | $8→$10 | 維護 | 等重 |
| 2019年11月12日 | - | 摩根大通 | 升級 | 減重→中性 | |
| 2019年8月11日 | -26.59% | 派珀·桑德勒 | $6→$7 | 維護 | 中性 |
| 2019年10月17日 | - | 加貝利公司 | 升級 | 持有→購買 | |
| 2019年09月30日 | -16.1% | 富國銀行 | $17→$8 | 維護 | 市場表現 |
| 2019/12/09 | - | 古根海姆 | 開始承保 | →中性 | |
| 2019年06月09日 | -26.59% | 摩根大通 | $9→$7 | 維護 | 體重不足 |
| 2019年08月09日 | -5.61% | 蒙特利爾銀行資本 | $11→$9 | 維護 | 市場表現 |
| 2019年07月15日 | -37.07% | 摩根士丹利 | $16→$6 | 評級下調 | 等重→減碼 |
| 2019年07月10日 | - | 瑞士信貸 | 假設 | →中性 | |
| 2019年6月11日 | -16.1% | 巴克萊 | →$8 | 開始承保 | →減持 |
| 2019年03月06日 | 25.85% | 奧本海默 | →$12 | 升級 | →表現強於大盤 |
| 2019年05月30日 | -5.61% | B of A證券 | $19→$9 | 評級下調 | 購買表現不佳的→ |
| 2019年05月28日 | 25.85% | 瑞銀集團 | $22→$12 | 評級下調 | 購買→中性 |
| 2019年05月09日 | 78.29% | 富國銀行 | $18→$17 | 維護 | 市場表現 |
| 2019年4月11日 | 141.22% | 花旗集團 | $27→$23 | 維護 | 買 |
| 2019/04/03 | 88.78% | 富國銀行 | $20→$18 | 維護 | 市場表現 |
| 2019/03/28 | 88.78% | 蒙特利爾銀行資本 | →$18 | 開始承保 | →市場表現 |
| 2019/03/20 | 78.29% | SunTrust Robinson Humphrey | →$17 | 開始承保 | →保留 |
| 2019年07月03日 | 130.73% | 瑞銀集團 | →$22 | 恢復 | →購買 |
| 2019年03月06日 | 78.29% | 摩根士丹利 | →$17 | 評級下調 | 超重→等重 |
| 2019年02月14日 | 109.75% | 瑞士信貸 | $26→$20 | 維護 | 中性 |
| 2019年02月14日 | - | 雷蒙德·詹姆斯 | 升級 | 市場表現優於→ | |
| 2019年01月23日 | 67.8% | 派珀·桑德勒 | $15→$16 | 升級 | 減重→中性 |
| 2019年03月01日 | - | B of A證券 | 升級 | 表現不佳的→收購 | |
| 2018年11月05日 | 183.17% | 摩根士丹利 | →$27 | 升級 | 等重→超重 |
| 11/02/2018 | 109.75% | B of A證券 | $19→$20 | 維護 | 表現不佳 |
| 10/01/2018 | 214.63% | 高盛 | →$30 | 維護 | 買 |
| 10/01/2018 | - | 利林克·斯旺 | 升級 | 表現遜於→市場表現 | |
| 2018年09月17日 | 204.14% | 瑞穗 | $28→$29 | 維護 | 買 |
| 2018年09月17日 | 172.68% | 瑞士信貸 | $23→$26 | 維護 | 中性 |
| 2018年09月17日 | - | BTIG | 升級 | 賣出→中性 |
What is the target price for Teva Pharmaceutical Indus (TEVA)?
Teva Pharmtics Indus(Teva)的目標價格是多少？
The latest price target for Teva Pharmaceutical Indus (NYSE: TEVA) was reported by B of A Securities on September 8, 2023. The analyst firm set a price target for $13.00 expecting TEVA to rise to within 12 months (a possible 36.34% upside). 11 analyst firms have reported ratings in the last year.
美國銀行證券於2023年9月8日報告了Teva製藥Indus(紐約證券交易所代碼：Teva)的最新目標價。這家分析公司將目標價定為13.00美元，預計Teva將在12個月內上漲(可能上漲36.34%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Teva Pharmaceutical Indus (TEVA)?
Teva製藥工業(Teva)的最新分析師評級是多少？
The latest analyst rating for Teva Pharmaceutical Indus (NYSE: TEVA) was provided by B of A Securities, and Teva Pharmaceutical Indus maintained their buy rating.
對Teva製藥工業公司(紐約證券交易所代碼：Teva)的最新分析師評級由美國銀行證券公司提供，Teva製藥工業公司維持其買入評級。
When is the next analyst rating going to be posted or updated for Teva Pharmaceutical Indus (TEVA)?
下一次分析師對Teva製藥工業(Teva)的評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Teva Pharmaceutical Indus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Teva Pharmaceutical Indus was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查看公共財務報表，與Teva製藥工業的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Teva製藥Indus的最後一次評級是在2023年9月8日提交的，所以你應該預計下一次評級將在2024年9月8日左右的某個時候提供。
Is the Analyst Rating Teva Pharmaceutical Indus (TEVA) correct?
分析師對Teva Pharmtics Indus(Teva)的評級正確嗎？
While ratings are subjective and will change, the latest Teva Pharmaceutical Indus (TEVA) rating was a maintained with a price target of $12.00 to $13.00. The current price Teva Pharmaceutical Indus (TEVA) is trading at is $9.54, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Teva製藥工業(Teva)評級保持不變，目標價在12.00美元至13.00美元之間。Teva Pharmtics Indus(Teva)目前的交易價格為9.54美元，超出了分析師的預測區間。